01/11/2023
TUDCA-ALS End of Double-Blind Phase III Trial.
The phase III clinical trial spanning seven EU countries, trialling the safety and efficacy of tauroursodeoxycholic acid (TUDCA) as a treatment to slow progression of ALS, has been completed. The top line results are expected to be announced by the end of December 2023.
The project has been coordinated by Professor Alberto Albanese, who says ‘At the moment, there is no cure for ALS and the few limited treatments currently available slow down disease progression by only a few months. An initial pilot study on 60 patients recently showed that TUDCA significantly delayed the degeneration of motor neurons in ALS patients by about one third, thus allowing for longer survival.’
TUDCA is a key compound in the Glutamed ND formula. We are encouraged by the findings to date and look forward to the results of this very important clinical trial ⌛️📈
The TUDCA-ALS Consortium spans seven countries in the EU and is formed by 10 partner organisations who are coming together to conduct this new Phase III clinical trial testing the safety and efficacy of Tauroursodeoxycholic acid (TUDCA) as a treatment to slow progression of amyotrophic lateral scler...
